Pfizer Inc. announced a significant realignment of its long-term business strategy on April 18, 2026, marking a definitive pivot toward the metabolic health and obesity sectors. The pharmaceutical giant confirmed it has recorded a $4.4 billion non-cash impairment charge related to its COVID-19 product portfolio, specifically the Comirnaty vaccine and the antiviral treatment Paxlovid. This financial adjustment follows a multi-quarter trend of diminishing global demand for pandemic-related therapies, which had previously served as the company's primary revenue drivers.
Chief Executive Officer Albert Bourla stated that the decision to write down these assets is part of a broader effort to optimize the company’s capital allocation. The restructuring comes as Pfizer prepares for a period of intensified competition resulting from a looming patent cliff. Several of the company’s blockbuster medications, including the anticoagulant Eliquis and the breast cancer therapy Ibrance, are scheduled to lose patent protection between 2026 and 2028. Pfizer estimates that these expirations could result in a combined annual revenue loss of approximately $17 billion by the end of the decade.
To mitigate these losses, Pfizer is reallocating its research and development resources toward its obesity pipeline. The company has committed to investing an additional $2.5 billion into metabolic research over the next two fiscal years, drawing funds from its infectious disease and oncology divisions. A primary focus of this investment is the development of danuglipron, an oral GLP-1 receptor agonist. Following successful Phase 2b results, Pfizer has officially launched a series of Phase 3 clinical trials, known as the VELOCITY program, to evaluate the drug’s efficacy in both weight loss and long-term weight management.
Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer, detailed that the company is specifically targeting a once-daily oral formulation to differentiate its offering from the injectable treatments currently dominating the market. The company’s internal projections suggest that the global market for obesity medications could exceed $100 billion by 2030, and Pfizer aims to secure a double-digit market share through its oral delivery platform.
In addition to internal R&D shifts, the company is integrating technologies from its $43 billion acquisition of Seagen to bolster its metabolic research capabilities. The April 18 announcement also included a revision of the company’s five-year strategic plan, which now prioritizes the launch of at least three new metabolic therapies by 2029. Pfizer’s leadership emphasized that this transition is essential for maintaining the company’s growth trajectory as it navigates the transition away from its pandemic-era business model.